Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Clinical Trials in China / NCT07003828
Active, not recruiting Observational

Hemodialysis-Induced Renal Perfusion Decline: Unraveling the Pathophysiological Mechanisms Linking Intradialytic Circulatory Stress to Residual Renal Function Loss

NCT07003828 · tracked via the Priya Life Science China tracker
Sponsor
Yuanjun Yang
Phase
Observational
Started
2024-05-01
Last updated
2025-06-04

Condition(s) studied

End-Stage Renal Disease Requiring Haemodialysis

Investigational drug(s) / intervention(s)

CEUS examinations

CEUS examinations: CEUS examinations were performed at three predetermined time points during each HD session: immediately before, 3 hours after HD initiation, and 15 minutes post-dialysis.

Study summary

Residual renal function (RRF) plays a critical role in quality of life and survival in hemodialysis (HD) patients but characteristically declines after the initiation of HD. Owing to incomplete understanding of the pathophysiology underlying RRF decline, protective strategies remain limited. The aim of this study was to characterize the changes in renal perfusion in incident HD patients with preserved RRF during dialysis sessions and to provide new strategies for RRF preservation.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * (1) adult patients with end-stage renal disease (ESRD) within 3 months of commencing HD; (2) preserved RRF defined as urinary output \>500 mL/24 h or eGFR ≥3 mL/min/1.73 m² Exclusion Criteria: * (1) known allergy to sulfur hexafluoride microbubbles (SonoVue®) microbubbles; (2) vascular access dysfunction; (3) combined peritoneal dialysis; (4)severe cardiopulmonary disease; (5) active infection or malignancy; (6) communicable diseases; (7) pregnancy or breastfeeding; (8) participation in other clinical trials.

Primary outcome measure(s)

  • Renal perfusion — at three time points during the HD session: pre-dialysis baseline, intradialytic phase (3 hours post-initiation)
    Renal perfusion was quantified using the CEUS-assessed perfusion index (PI). The primary outcome measure was the PI.

Trial sites (1)

FacilityCityRegionStatus
the First Medical Center of Chinese PLA General Hospital Beijing China

More Yuanjun Yang trials in China

Effect of Glycosuria on Urinary Protein in Patients With Chronic Kidney Disease Treated With SGLT2 Inhibitors Active, not recruiting
The Renal Protective Effects of Remote Ischemic Preconditioning in Patients With Chronic Kidney Disease Recruiting

Other trials for the same condition

Inferior Vena Cava Collapsibility Index and Intradialytic Hypotension Recruiting
To Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of KN060 in ESRD Dialysis Patients Recruiting
Predictive Value of Carotid Ultrasonography for Intradialytic Hypotension Recruiting
Pleth Variability Index for Predicting Low Blood Pressure During Maintenance Hemodialysis Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07003828 on ClinicalTrials.gov ↗ ← All trials in China